Gannax Pharma
A Chinese biotech developing novel drugs in the field of NASH and PBC.
Gannex is a subsidiary of Hong Kong-listed Ascletis Pharma (HKEX:1672), a Shanghai-headquartered company focused on viral diseases, oncology and NASH. It has two clinical stage NASH drug candidates with global rights against two different targets (THRβ and FXR) and one clinical-stage PBC drug candidate.
Latest Gannax Pharma News & Features
10 September 2020
13 February 2019
20 September 2018
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze